Oral Wegovy cleared

Weight-loss drugs called glucagon-like peptide-1 medicines work by copying a gut hormone that slows stomach emptying and helps the brain register fullness, which is why people often eat less without white-knuckle dieting. Semaglutide is the ingredient in Wegovy, and until now the obesity version in the United States was mainly known as a weekly shot. (fda.gov) The hard part has been turning that kind of drug into a pill, because stomach acid and digestive enzymes are built to break proteins apart before they reach the bloodstream. Novo Nordisk’s tablet uses semaglutide in an oral form designed for once-daily use, and the Food and Drug Administration cleared it for chronic weight management in adults in late December 2025. (fda.gov) (prnewswire.com) The approval rested on a Phase 3 study called OASIS 4, which followed 307 adults for 64 weeks. The trial enrolled people with obesity, or people with overweight plus at least one weight-related medical problem, and it excluded people with diabetes. (acc.org) (novonordisk.mediaroom.com) In that study, people taking oral semaglutide 25 milligrams lost 13.6% of body weight on average by week 64, while the placebo group lost 2.2%. A second analysis estimated about 17.4% weight loss among participants who stayed on treatment for the full study. (acc.org) (prnewswire.com) The side effects looked familiar to anyone who has followed this drug class: nausea, diarrhea, vomiting, constipation, belly pain, headache, and indigestion were among the common problems in the label. The boxed warning stayed the same too, warning about thyroid C-cell tumors seen in rodents and advising against use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (fda.gov) The pill does not erase the tradeoff that usually comes with oral semaglutide: timing. The prescribing information says to take it once each morning on an empty stomach with no more than 4 ounces of plain water, and then wait at least 30 minutes before eating, drinking, or taking other oral medicines. (fda.gov) (wegovy.com) That routine sounds small on paper, but it changes who can realistically stay on treatment. A weekly injection asks you to tolerate a needle; a daily pill asks you to build your morning around it. (wegovy.com) (biospace.com) Novo Nordisk said when the approval was announced that it was preparing a full United States launch in early January 2026 and making the tablets in North Carolina. Company materials for prescribers now list both the weekly 2.4 milligram injection and the 25 milligram tablet under the Wegovy brand. (prnewswire.com) (novomedlink.com) The bigger shift is that obesity treatment is starting to split into two lanes: medicines that work like long-acting weekly tools, and medicines that fit more like standard daily prescriptions. Oral Wegovy gives doctors one more way to match the same semaglutide molecule to the practical reality that some patients will accept a shot, and some will only start with a pill. (fda.gov) (appliedclinicaltrialsonline.com)